MAPK pathway and NIS in B-CPAP human papillary thyroid carcinoma cells treated with resveratrol

Basit Öğe Kaydı
dc.authorid0000-0002-1849-3179
dc.authorid0000-0002-4799-1836
dc.authorid0009-0005-0622-4202
dc.authorid0000-0003-1809-2655
dc.contributor.authorUnal Kocabas, Gokcen
dc.contributor.authorBlatti, Asli Kisim
dc.contributor.authorBerdeli, Afig
dc.contributor.authorOzgen, Ahmet Gokhan
dc.contributor.authorYurekli, Banu Sarer
dc.date.accessioned2025-04-18T11:03:30Z
dc.date.available2025-04-18T11:03:30Z
dc.date.issued2024
dc.departmentEge Üniversitesi, Tıp Fakültesi, Cerrahi Bilimler Bölümü, Tıbbi Patoloji Ana Bilim Dalı
dc.description.abstractBackground: Resveratrol, a herbal phytoalexin, is known to have anti-tumor effects in several tumors including thyroid cancer cells. Aim: The aim of this study was to determine the effects of resveratrol on the expression of BRAF, ERK and NIS mRNA levels and protein expression in B-CPAP human thyroid papillary cancer cell line. Methods: B-CPAP cells were treated with resveratrol at concentrations of 10-100 mu M for 24-48-72 h. Cell viability was assessed by XTT Cell Proliferation Assay. BRAF, ERK and NIS mRNA levels were evaluated by rtPCR method. Protein expressions were evaluated by Western Blot method. Results: Resveratrol was found to inhibit cell proliferation in a time and dose dependent manner. The IC50 values of resveratrol were 18.7 mu M and 56.8 mu M after 48 h and 72 h respectively. Resveratrol treatment of B-CPAP cells resulted in up to 1.5-fold reduction in BRAF mRNA and up to 5.5 fold reduction in ERK mRNA levels. NIS mRNA levels showed up to 3-fold increase. Western Blot studies confirmed the rt- PCR results with a decrease in BRAF and ERK, and increase in NIS protein expressions. Conclusion: This study demonstrated that resveratrol inhibits thyroid papillary carcinoma cell proliferation and reduces poor prognostic BRAF and ERK mRNA and protein expressions, while increasing NIS mRNA and protein expression suggesting a redifferentiating effect. More studies are needed to evaluate resveratrol as a novel therapeutic agent in the treatment of papillary thyroid cancer.
dc.identifier.citationUnal Kocabas, G., Kisim Blatti, A., Berdeli, A., Ozgen, A. G., & Sarer Yurekli, B. (2024). MAPK pathway and NIS in B-CPAP human papillary thyroid carcinoma cells treated with resveratrol. Pathology, Research and Practice, 263, 155623.
dc.identifier.doi10.1016/j.prp.2024.155623
dc.identifier.endpage5
dc.identifier.issn16180631
dc.identifier.issueNov
dc.identifier.pmid39405802
dc.identifier.scopus2-s2.0-85208772709
dc.identifier.scopusqualityQ2
dc.identifier.startpage1
dc.identifier.urihttps://doi.org/10.1016/j.prp.2024.155623
dc.identifier.urihttps://hdl.handle.net/11454/117119
dc.identifier.volume263
dc.identifier.wosWOS:001334814600001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorUnal Kocabas, Gokcen
dc.institutionauthorBerdeli, Afig
dc.institutionauthorOzgen, Ahmet Gokhan
dc.institutionauthorYurekli, Banu Sarer
dc.institutionauthorid0000-0002-1849-3179
dc.institutionauthorid0000-0002-4799-1836
dc.institutionauthorid0009-0005-0622-4202
dc.institutionauthorid0000-0003-1809-2655
dc.language.isoen
dc.publisherElsevier GMBH
dc.relation.ispartofPathology - Research and Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBRAF
dc.subjectERK
dc.subjectNIS
dc.subjectResveratrol
dc.subjectThyroid papillary cancer
dc.titleMAPK pathway and NIS in B-CPAP human papillary thyroid carcinoma cells treated with resveratrol
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu